Glythera Limited is a biotechnology company specializing in the development of next generation biotherapeutics, through the application of their advanced proprietary linker and stable glycan technologies: PermaLink™ and PermaCarb™.

Project Overview

Glythera requested an assessment of DARs for an antibody-drug-conjugate (ADC) product in plasma samples derived from mouse Pharmacokinetic (PK) studies. The purpose of the project was to use a customized method to provide quantitative data for each PK time point in order to calculate the corresponding DARs.

Technical Considerations – Candidate Peptide Selection

A method development phase using high-resolution Q-TOF instrumentation was used to first select candidate marker and drug-conjugated peptides that were structurally stable and could be consistently followed in the PK assessment. Cold isotope-labelling is the method of choice for validating the PK data sets derived from MS studies.

Client Testimonial

“The specific expertise surrounding quantitative mass spectrometry at BioPharmaSpec is excellent and Glythera benefitted greatly from the technical approaches used during method development and optimization” – Senior Development Scientist, Glythera